- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Granules India Limited — Updates, 08-01-2026: Press Release
08-01-2026 | 08:30 am
08-01-2026 | 08:30 am
Granules Pharmaceuticals received FDA tentative approval for generic Amphetamine Extended-Release Tablets (gDYANAVEL XR), eligible for 180-day exclusivity. This ADHD treatment targets a USD 41 million market. It's their second FDA tentative approval in weeks, following a USD 172 million market opportunity for generic ADZENYS XR-ODT®.
No comments yet. Be the first to comment!